Conference Coverage
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Clinical Topics & News
VA Launches Virtual Tumor Board
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.
Conference Coverage
Pembro/chemo combo fails to improve event-free survival in head and neck cancer
Some trends favored chemoradiation plus pembrolizumab over chemoradiation alone, but KEYNOTE-412 failed to meet primary endpoint.
Conference Coverage
In NSCLC, not all EGFR mutations are the same
Patients with the Ex20 insertion may buck trend by responding well to ICIs.
Conference Coverage
In early NSCLC, comorbidities linked to survival
Respiratory and cardiometabolic comorbidities were associated with significantly worse overall survival in lung cancer.
Conference Coverage
‘Smoking gun–level’ evidence found linking air pollution with lung cancer
The finding could lead to strategies for preventing lung cancer in nonsmokers exposed to high levels of foul air.
Conference Coverage
Gene mutations may drive lung cancer in never-smokers
Study hints at mechanistic differences between small cell lung cancer in smokers versus nonsmokers.
Conference Coverage
Cabozantinib boosts dual immunotherapy in advanced RCC
The new study suggests triplet therapy may become a new standard of care in advanced renal cell carcinoma.
Conference Coverage
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat
Nirogacestat has shown a significant improvement in progression-free survival and also a reduction in symptoms and better quality of life.